Listing of Claims:

The listing of claims presented below reflects the pending claims in the instant application as of the mailing date of the Office Action (i.e., March 27, 2007). No amendments have been made herein to the pending claims, and this listing of claims has been provided solely for the Examiner's convenience.

1. (Previously Presented) An aptamer-toxin conjugate therapeutic agent comprising a targeting moiety conjugated to a cytotoxic moiety wherein said targeting moiety is an aptamer specific for PSMA (Prostate Specific Membrane Antigen).

2-3. (Cancelled)

4. (Previously Presented) The therapeutic agent of claim 1 wherein said cytotoxic moiety is a small molecule chemotherapeutic agent.

5. (Withdrawn) The therapeutic agent of claim 3 wherein said cytotoxic moiety is selected from the group consisting of a cytotoxic peptide, a cytotoxic protein, a small molecule chemotherapeutic agent, and a radioisotope therapeutic molecule.

6. (Original) The therapeutic agent of claim 4, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.

7. (Withdrawn) The therapeutic agent of claim 5, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.

8. (Withdrawn) The therapeutic agent of claim 4 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.

9. (Withdrawn) The therapeutic agent of claim 5 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.

10. (Previously Presented) An aptamer-drug conjugate comprising one or more aptamers, wherein at least one aptamer is specific for a PSMA (Prostate Specific Membrane

Antigen), and a drug linked by a linker and having the formula: $(aptamer)_n$ -- linker -- $(drug)_m$, wherein n is between 1 and 10 and m is between 1 and 20.

11. (Cancelled)

12. (Withdrawn) The aptamer-drug conjugate of claim 10, wherein at least one of the one or more aptamers is specific for a target selected from the group consisting of PSMA, PSCA, e-selectin, an ephrin, ephB2, cripto-1, TENB2 (TEMFF2), ERBB2 receptor (HER2), MUC1, CD44v6, CD6, CD19, CD20, CD22, CD23, CD25, CD30, CD33, CD56, IL-2 receptor, HLA-DR10β subunit, EGFRvIII, MN antigen, caveolin-1 and nucleolin the target PSMA.

13. (Original) The aptamer-drug conjugate of claim 10, wherein the drug is a cytotoxin.

14. (Previously Presented) The aptamer-drug conjugate of claim 10, wherein the drug is a vinca alkaloid.

15. (Previously Presented) The aptamer-drug conjugate of claim 10, wherein the drug is desacetyl vinblastine 3-carboxhydrazide (DAVCH).

16. (Original) The aptamer-drug conjugate of claim 10, wherein the linker comprises one or more nucleophilic moieties, one or more electrophilic moieties or combinations thereof.

17. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of a Boc-protected amine, a Boc-protected amine on a heterobifunctional linker, a nucleophilic dendrimer, an electrophilic dendrimer and an electrophilic comb polymer.

18. (Original) The aptamer-drug conjugate of claim 10, wherein the linker is selected from the group consisting of Boc-NH2-PEG-NHS, an erythritol dendrimer, an octa-polyethylene glycol dendrimer and comb polymer.